Literature DB >> 10404366

Use of a polylysine-saporin conjugate to prevent posterior capsule opacification.

R H Bretton1, A Swearingen, R L Kash, R Cooley.   

Abstract

PURPOSE: To determine the feasibility of applying a polylysine-saporin (PLS) conjugate to the lens capsule at surgery to prevent lens epithelial cell (LEC) proliferation and posterior capsule opacification (PCO).
SETTING: Department of Research & Development, Bausch & Lomb Surgical, and Department of Ophthalmology, Saint Louis University, St. Louis, Missouri, USA.
METHODS: Fluorescein-labeled polylysine was applied to the lens capsule of rabbits after phacoemulsification and analyzed histologically to determine the extent of binding to the lens capsule and surrounding tissues. The cytotoxin saporin was conjugated to polylysine using bifunctional cross-linkers. This PLS conjugate was applied to LECs in culture and to the lens capsules of rabbits. These eyes were monitored for PCO.
RESULTS: Polylysine primarily bound to the lens capsule membranes, with little or no binding to surrounding tissues. When PLS was added to LECs in culture, it was internalized and destroyed the cells. Of 9 rabbit eyes treated with PLS during surgery, 1 remained free of PCO for the life of the animal (40 weeks), while 6 showed a delay of cortical regrowth approximately 2 to 3 times that of control eyes.
CONCLUSIONS: Polylysine bound selectively to the lens capsule membrane. The PLS conjugation resulted in a toxic agent that targeted the lens capsule and destroyed proliferating LECs. The application of a PLS conjugate during surgery may prevent PCO.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404366     DOI: 10.1016/s0886-3350(99)00076-0

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  2 in total

Review 1.  [New methods for the prevention of posterior capsule opacification].

Authors:  G U Auffarth; T M Rabsilber; A J Reuland
Journal:  Ophthalmologe       Date:  2005-06       Impact factor: 1.059

2.  Nanostructured lipid carrier surface modified with Eudragit RS 100 and its potential ophthalmic functions.

Authors:  Wenji Zhang; Xuedong Li; Tiantian Ye; Fen Chen; Shihui Yu; Jianting Chen; Xinggang Yang; Na Yang; Jinsong Zhang; Jinlu Liu; Weisan Pan; Jun Kong
Journal:  Int J Nanomedicine       Date:  2014-09-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.